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FurinSevere acute respiratory syndrome coronavirus (SARS-CoV) poses a considerable threat to human health.
Activation of the viral spike (S)-protein by host cell proteases is essential for viral infectivity. However, the
cleavage sites in SARS-S and the protease(s) activating SARS-S are incompletely deﬁned. We found that R667
was dispensable for SARS-S-driven virus–cell fusion and for SARS-S-activation by trypsin and cathepsin L in a
virus–virus fusion assay. Mutation T760R, which optimizes theminimal furin consensus motif 758-RXXR-762,
and furin overexpression augmented SARS-S activity, but did not result in detectable SARS-S cleavage. Finally,
SARS-S-driven cell–cell fusion was independent of cathepsin L, a protease essential for virus–cell fusion.
Instead, a so far unknown leupeptin-sensitive host cell protease activated cellular SARS-S for fusion with
target cells expressing high levels of ACE2. Thus, different host cell proteases activate SARS-S for virus–cell
and cell–cell fusion and SARS-S cleavage at R667 and 758-RXXR-762 can be dispensable for SARS-S activation.search Institute, 270 Masonic
esearch Center, Kellnerweg 4,
immons),
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
A novel coronavirus (CoV) has been identiﬁed as the causative
agent of severe acute respiratory syndrome (SARS), which claimed
almost 800 lives in 2002–03 (Drosten et al., 2003; Ksiazek et al., 2003;
Peiris et al., 2004). Coronaviruses, including SARS-CoV, harbour three
envelope proteins, spike (S), membrane (M), and envelope (E), which
are required for virion assembly, release and infectious entry into
target cells (Masters, 2006). The SARS-CoV-S-protein (SARS-S)
mediates infectious cellular entry (Hofmann et al., 2004b; Simmons
et al., 2003; Yang et al., 2004) and constitutes the major target of the
neutralizing antibody response (Hofmann and Pöhlmann, 2004; Nie
et al., 2004b, 2004a). The carboxypeptidase angiotensin-converting
enzyme 2 (ACE2) is used by SARS-CoV as receptor for cell entry (Li et
al., 2003; Wang et al., 2004) and is expressed on type II pneumocytes,the major viral target cells (Hamming et al., 2004; Mossel et al., 2008;
To et al., 2004). Several cellular C-type lectins augment or facilitate
SARS-S-driven entry (Gramberg et al., 2005; Jeffers et al., 2004; Marzi
et al., 2004; Yang et al., 2004). However, ACE2 but not C-type lectin
expression correlates with susceptibility to SARS-S-driven infection
(Hofmann et al., 2004a; Nie et al., 2004b) and is essential for SARS-
CoV spread in experimentally infected mice (Kuba et al., 2005),
indicating that ACE2 is a major and likely the only receptor used by
SARS-CoV in the infected host. Collectively, SARS-S interacts with host
cell factors to mediate the ﬁrst essential step in the viral life cycle,
virus entry into target cells, and constitutes an attractive target for
preventive and therapeutic approaches.
The SARS-S-protein is synthesized in the constitutive secretory
pathway of infected cells. Amino acid motifs in its cytoplasmic tail slow
down transit through the Golgi compartment (McBride et al., 2007)
where interactions with the M-protein facilitate virion incorporation
(McBride and Machamer, 2010; Voss et al., 2009). The structural
organization of SARS-S is similar to that of several other viral envelope
proteins, termed class I fusion proteins: The extracellular S1 domain
facilitates binding to the receptor, ACE2, while the membrane-anchored
S2 domain harbours the functional elements required for fusion of the
viral with a target cell membrane (Hofmann and Pöhlmann, 2004). Viral
class I fusion proteins are usually synthesized in an inactive form, and
Fig. 1.Domain organization of the SARS-CoV spike-protein, including potential cleavage
sites. The mutations introduced into the SARS-S are depicted. The box indicates a
potential furin cleavage motif. HR, heptad repeat; SP, signal peptide; T, transmembrane
domain; CT, cytoplasmic domain.
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state (Eckert andKim, 2001;Harrison, 2008). However, viral strategies to
accomplish proteolytic activation can vary. For instance, the majority of
strainsof themurinecoronavirusmousehepatitis virus (MHV)contain S-
proteins that are cleaved by furin in infected cells, and these viruses are
believed to enter target cells by receptor-dependent, pH-independent
fusion with the plasma membrane (de Haan et al., 2004; Nash and
Buchmeier, 1997; Qiu et al., 2006), although some of these ﬁndings are
controversial (Eifart et al., 2007). In contrast, the S-protein of the MHV
type 2 strain is not cleaved by furin and the spike protein on incoming
virions is activated in target cell vesicles by endosomal proteases of the
cathepsin family (Qiu et al., 2006).
Similar to MHV-2, proteolytic activation of SARS-S is mediated by
cathepsins in target cells, most importantly by cathepsin L (Simmons
et al., 2005). Cleavage-activation by cathepsin L is thought to require
previous binding of SARS-S to ACE2, which is believed to induce a
conformational change in the S-protein (Simmons et al., 2005), and
seems to involve at least two consecutive proteolytic processing steps
(Belouzard et al., 2009; Simmons et al., 2005). However, the cleavage
sites in SARS-S have been incompletely deﬁned. Arginine 667 was
shown to be required for the robust augmentation of SARS-S-driven
cell–cell (Belouzard et al., 2009; Follis et al., 2006) and virus–cell
fusion (Kam et al., 2009) by trypsin and for the trypsin-dependent
circumvention of the entry blockade imposed by lysosomotropic
agents (Belouzard et al., 2009). In spite of these results, it is at present
unknown if R667 is required for SARS-S activation by cathepsin L.
Recent evidence suggests that R797 is a component of a second
cleavage site (Belouzard et al., 2009; Watanabe et al., 2008). Thus,
similar as for R667, residue R797 was demonstrated to be required for
trypsin-dependent augmentation of SARS-S-dependent membrane
fusion and for trypsin-dependent resistance to lysosomotropic agents
(Belouzard et al., 2009). Nevertheless, efﬁcient proteolytic processing
of wild-type SARS-S at this site, or at any other site, has so far not been
demonstrated in cells (Hofmann et al., 2004b; Simmons et al., 2004;
Xiao et al., 2003; Yang et al., 2004; Yao et al., 2004), with one
exception (Wu et al., 2004). Notably, the SARS-S-protein contains a
minimal furin cleavage site at position 758–761 (RNTR), and a peptide
comprising this sequence is efﬁciently cleaved by furin (Bergeron et
al., 2005). However, the contribution of the RNTR motif to proteolytic
activation of SARS-S is unknown.
In order to explore the role of the minimal furin cleavage site at
position 758–761 and to further investigate the importance of the
protease sensitive site at position R667, we analyzed the SARS-S
mutantsR667Aand T760R. Our analysis revealed theR667was required
for responsiveness to trypsin-treatment in some experimental systems
but had no effect on SARS-S activation by trypsin and cathepsin L in a
virus–virus fusion assay, which adequately mimics, in isolation, the
conditions required for SARS-S-driven membrane fusion, suggesting
thatR667might not play amajor role in SARS-S activation in target cells.
Mutation T760R, which optimized an existing minimal furin cleavage
motif, increased SARS-S activity but no evidence for cleavage of mutant
T760R was obtained. Finally, our results demonstrate the cathepsin L
activates SARS-S for virus–cell but not cell–cell fusion, which was
dependenton the activityof a so far uncharacterized serineprotease (for
fusion with targets expressing high amounts of ACE2) or addition of
exogenous trypsin (for fusion with targets expressing low amounts of
ACE2).
Results
Residue R667 but not K672 determines sensitivity of SARS-S to inactivation
by trypsin
Based on alignments with other coronaviruses, it has been
suggested that residues R667 and K672 deﬁne a potential cleavage
site for host cell proteases (Bergeron et al., 2005; Follis et al., 2006). Todetermine the importance of these residues for SARS-S sensitivity to
proteolysis, we introduced mutations R667A or K672L into wt SARS-S
(Fig. 1). Analysis of the SARS-S mutants by lentiviral pseudotyping, an
experimental approach which adequately models SARS-S-driven
entry into target cells (Hofmann et al., 2004b; Moore et al., 2004;
Simmons et al., 2004), showed that the mutations R667A and K672L
were both compatible with robust SARS-S-driven virion incorporation
and entry (Figs. 2A and B), albeit the entry efﬁciency of viruses
harbouring the mutant S-proteins was somewhat reduced compared
to pseudotypes bearing wt SARS-S (Fig. 2A). Similar results were seen
with a R667A and K672L double mutant (wt SARS-S: 44,390±
3286 counts per second (c.p.s.), R667A/K672DL: 39,953±1329 c.p.s.),
demonstrating that these particular basic residues are not required for
infectious entry in tissue culture.
We next assessed if the exchanges R667A and K672L altered
sensitivity of SARS-S-bearing pseudotypes to trypsin treatment, which
was previously shown to inactivate cell-free virions (Simmons et al.,
2004, 2005). Indeed, pre-treatment of pseudotypes bearing wt SARS-S
and SARS-Smutant K672L reduced viral infectivity in a dose-dependent
manner (Fig. 2C). In contrast, SARS-S mutant R667A was resistant to
inactivation by trypsin (Figs. 2B and C), indicating that R667 deﬁnes a
trypsin-sensitive site and that cleavage at this site abrogates infectivity
of free virions. To further characterize the importanceofR667 for SARS-S
sensitivity to proteolysis, we compared pseudotypes bearing wt SARS-S
and SARS-S mutant R667A for their sensitivities to inactivation by a
panel of proteases. Treatment with trypsin, plasmin factor Xa and, to a
lesser extent, thrombin reduced infectivity of viruses harbouring wt
SARS-S but not SARS-Smutant R667A (Fig. 2D), further underlining that
R667 deﬁnes a protease sensitive site. Thermolysin and chymotrypsin
treatment also diminished viral infectivity, but wt SARS-S and SARS-S
mutant R667Awere equally sensitive to inactivation by these proteases
(Fig. 2D), indicating that they cleave SARS-S at a site distinct fromR667.
Collectively, R667 but not K672 deﬁnes a protease-sensitive site and
proteolysis of cell-free virions at this site abrogates viral infectivity.
Residue R667 is indispensable for trypsin-induced infection of target cells
treated with ammonium chloride
Lysosomotropic agents, such as ammonium chloride, interfere with
endosomal acidiﬁcation and block infectious entry of SARS-CoV
(Hofmann et al., 2004b; Simmons et al., 2004; Yang et al., 2004),
presumably by inhibiting cathepsins, which require low pH for optimal
activity. Treatment of cell-bound viruswith trypsin was shown to allow
infectious SARS-S-driven entry into ammonium chloride-treated cells
(Simmons et al., 2005), indicating that trypsin can functionally replace
cathepsin L as a SARS-S-activating protease under these conditions
(“trypsin bypass”). We asked if R667 is required for a trypsin bypass of
endosomal acidiﬁcation. Treatment of target cells with ammonium
chloride markedly inhibited infectious entry driven by wt SARS-S and
SARS-S mutant R667A, and infectivity of wt SARS-S-bearing viruses
could be fully restored by treatment of cell-bound virions with trypsin
(Fig. 3). In contrast, infectivity of R667A bearing virionswas not rescued
by trypsin treatment (Fig. 3), indicating that R667 is required for
activation of cell-bound virions by trypsin.
Fig. 2. Role of R667 and K672 in SARS-CoV entry and inactivation. (A) Infectivity of pseudovirions bearing wild-type SARS-S and SARS-S variants R667A or K672L or no envelope
protein (control) for VeroE6 cells. Results are presented asmeans and standard deviations of triplicate wells. Similar results were seen in 293T and 293T-ACE2 cells. (B) Expression of
SARS-S and mutant SARS-S-proteins on pseudovirions. Equal volumes of virus stocks were concentrated by ultracentrifugation through a sucrose gradient, treated with PBS or
trypsin and spike-proteins were detected using a monoclonal antibody directed against the N-terminal portion of SARS-S. (C) Trypsin inactivation of pseudotypes bearing SARS-S or
mutant SARS-S proteins. Ultracentrifuge-concentrated virus was pretreated with varying concentrations of TPCK-trypsin for 10 min at 25 °C, before trypsin inactivation and spin
infection of 293T-ACE2 cells. Results are presented relative to infectivity measured for untreated virions and are means and standard deviations of triplicate wells. (D) Inactivation of
SARS-S and SARS-S mutant R667A by various proteases prior to infection of 293T-ACE2 cells. Results are presented relative to the infectivity measured for untreated viruses and are
means and standard deviations of triplicate wells. Similar results were seen in two additional experiments.
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cathepsin L in a virus–virus fusion assay
We next assessed the impact of R667A on SARS-S proteolytic
activation in a virus–virus membrane-fusion assay. In this assay, SARS-Fig. 3. Trypsin bypass of wt SARS-S and SARS-S R667A infection of ammonium chloride
treated VeroE6 cells. Virus was allowed to bind, but not internalize into VeroE6 cells
pretreated with 20 mM ammonium chloride. Subsequently, the cells were treated with
TPCK-trypsin (10 μg/ml) to activate SARS-S formembrane fusion. Results are presented as
a percentage of no trypsin, no ammonium chloride control and are means and standard
deviations of triplicate wells. Similar results were seen on 293T-ACE2 cells.S-bearing viruses (which also contain the Avian Sarcoma Leukosis
Virus-A envelope protein, EnvA, in their membrane) are allowed to fuse
withACE2harbouringviruses. The fusion efﬁciency is thenquantiﬁedby
the addition of virions to leupeptin-treated (to exclude an impact of host
cell proteases on SARS-S activation) HeLa cells, which express the EnvA
receptor TvA, and which are not susceptible to SARS-S-driven infection
(Simmons et al., 2005). Thus, the virus–virus fusion assay is a
reductionistic model system, which allows the proteolytic activation of
SARS-S to proceed under cell-free conditions. Efﬁcient fusion of virions
bearing wt SARS-S with virions bearing ACE2 was only observed upon
treatment of particleswith trypsin and recombinant activated cathepsin L
(Fig. 4), in agreement with previously reported results (Simmons et al.,
2005). Strikingly, trypsin and cathepsin L treatment activated virions
bearing wt SARS-S and SARS-S mutant R667A with similar efﬁciency
(Fig. 4), demonstrating that R667 was dispensable for SARS-S activation
under these conditions. In summary, R667 deﬁnes a trypsin cleavage site,
which is responsible for trypsin-dependent activation of cell-bound and
inactivationof cell-freevirions, respectively.However,R667 isdispensable
in tissue culture infection and for SARS-S activation by trypsin and
cathepsin L in a virion-virion fusion assay, andmight thus be dispensable
for proteolytic activation of SARS-CoV in target cells.
Substitution T760R augments SARS-S-driven infection and cell–cell fusion
We hypothesized that the minimal furin cleavage site (RXXR) at
positions 758–761 might contribute to SARS-S-dependent membrane
fusion by allowing SARS-S cleavage, albeit with low efﬁciency. To
investigate the role of this motif in SARS-S-driven entry, we assessed if
Fig. 4. Protease activation of virus–virus fusion mediated by wt SARS-S and mutant
R667A. Pseudovirions bearing SARS-S or ACE2 were mixed and virion-fusion activated
by trypsin (10 μg/ml) or cathepsin L (2 μg/ml). Mock indicates the mock addition of
protease to mixed particles. In addition to this control, further controls of Spike-EnvA or
ACE-2 pseudotypes alone treated or untreated with protease are consistently below the
level of detection, as previously described (Simmons et al., 2005). Infection by
luciferase-encoding particles was determined using luciferase substrate as described by
the manufacturer (Promega). Results are presented as means and standard deviations
of replicates of four wells. Similar results were seen in 2 additional experiments.
Fig. 5. Activity ofwt SARS-S and variant T760R invirus–cell (left panel) and cell–cell fusion
(right panel) experiments. Left panel: Pseudoparticles harbouring the indicated SARS-S
proteinsor noS-protein as a controlwerenormalized for equal capsid content andused for
infection of 293T cells expressing either pcDNA3 or ACE2 in quadruplicates. Luciferase
activities were determined after 72 h. A representative experiment is shown, comparable
results were obtained in two independent experiments. Error bars indicate standard
deviation (SD). Right panel: 293T effector cells cotransfected with expression vectors
encoding the indicated S-proteins (or transfectedwith empty vector) in combinationwith
a GAL-VP16 expression plasmid were co-cultivated with target cells transfected with
either pcDNA3 or ACE2 plasmid togetherwith a plasmid encoding a GAL-VP16-responsive
luciferase reporter gene. Luciferase activities were measured two days after cocultivation.
The results of a representative experiment are shown andwere conﬁrmed in two separate
experiments. Error bars indicate SD.
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(resulting in the sequence RXRR, Fig. 1) affects SARS-S function.
Fluorescence-activated cell sorting analysis revealed that SARS-S
mutant T760R and wt SARS-S were expressed to comparable levels at
the surface of transfected 293T cells, and could thus be directly
compared in functional studies (Supplementary Fig. 1). We ﬁrst
determined if substitution T760R affected S-protein-driven infectious
entry. In order to assess infectious entry facilitated by the S-protein
variant, pseudotypes were used for infection of control or ACE2-
transfected 293T cells (Fig. 5, left panel). The 293T cell line expresses
endogenous ACE2 and is therefore susceptible to SARS-S-driven
infection (Hofmann et al., 2004b, 2004a; Li et al., 2003; Simmons et
al., 2004; Yang et al., 2004). Accordingly, infectious entry of SARS-S-
bearing pseudovirions into control transfected cells was detectable
(Fig. 5, left panel). Notably, entry driven by the T760R variantwas about
2-fold more efﬁcient than infection driven by SARS-S wt, and a similar
observation (4-fold increase) was made when infection of ACE2-
transfected cellswasexamined (Fig. 5, left panel), suggesting that T760R
augments S-protein activity. Indeed, when SARS-S-driven membrane
fusion was assessed in a previously reported cell–cell fusion assay
(Hofmann et al., 2006), which measures fusion of effector 293T cells
expressing S-proteins with 293T target cells expressing ACE2 or
pcDNA3, again the S-protein mutant was more active than SARS-S wt
(Fig. 5, right panel). Thus, the introduction of an arginine residue at
position 760 increases the membrane fusion activity of SARS-S.
Overexpression of furin enhances cell–cell and virus–cell fusion driven
by SARS-S wt and mutant T760R
Exchange T760R optimizes a minimal furin cleavage site in SARS-S
and might increase SARS-S activity by facilitating cleavage by furin or
related proteases.We investigated whether furin can augment SARS-S
activity by determining the infectivity of p24-normalized SARS-S
pseudotypes produced in the absence and presence of overexpressed
furin (Fig. 6, left panel). Overexpression of furin moderately increased
infectivity of pseudotypes bearing wt SARS-S or mutant T760R. The
most notable effect was observed for SARS-S wt pseudotypes, which
showed a ~7-fold augmented infectivity (Fig. 6, left panel), albeit this
increase was not statistically signiﬁcant. Comparable observations
were made when S-driven cell–cell fusion was examined, and the
increase in activity of wt SARS-S and mutant T760R observed uponfurin overexpression was statistically signiﬁcant (Fig. 6, right panel).
However, fusion driven by SARS-S wt and T760R were augmented to
similar degrees (about 2–3 fold) by furin overexpression. Thus, high
levels of furin enhance SARS-S-protein driven cell–cell and virus–cell
fusion.
Furin overexpression does not facilitate detectable cleavage of wt SARS-S
and mutant T760R
Our functional data showed that mutation of T760R and over-
expression of furin augmented SARS-S activity, presumably by
facilitating proteolytic processing of the S-protein. To assess SARS-S
cleavage, we conducted Western blot analyses of lysates of S-protein
transfected 293T cells, using a serum speciﬁc for the S2-portion of
SARS-S. Expression of ß-actin served as loading control. Our results
revealed a prominent band of approximately 160 kDa for both wt
SARS-S and mutant T760R (Fig. 7), which is expected for uncleaved
SARS-S (Hofmann et al., 2004b). Treatment of cells with trypsin before
lysis reduced the signal obtained for uncleaved SARS-S, and a band of
approximately 90 kDa appeared, in accordance with the previously
reported size of the S2-fragment of SARS-S (Bergeron et al., 2005;
Follis et al., 2006). Co-expression of furin with SARS-S wt or the S-
protein variant T760R did not result in the appearance of a S2-band,
indicating that furin-mediated cleavage was inefﬁcient or absent.
Virus–cell fusion but not cell–cell fusion by SARS-S wt and T760R
depends on cathepsin activity
We next investigated whether exchange T760R altered the
sensitivity of SARS-S-dependent membrane fusion to inhibition by
the cathepsin L and B inhibitor MDL 28170. In agreement with
published data (Simmons et al., 2005), MDL 28170 efﬁciently reduced
infection by SARS-S-bearing pseudotypes (Fig. 8, left panel). Similar
inhibition was observed with the SARS-S mutant T760R, indicating
that this change did not modulate cathepsin-dependence of viral
entry. In stark contrast, MDL 28170 had no inhibitory effect on wt
SARS-S and T760R dependent cell–cell fusion (Fig. 8, right panel),
Fig. 6. Impact of furin expression on virus–cell (left panel) and cell–cell fusion (right panel) driven by wt SARS-S and SARS-S variant T760R. Left panel: Pseudotypes harbouring the
indicated S-proteinswere prepared in the presence (white bars) or absence (black bars) of co-expressed furin. After normalization for p24-content, the particleswere used for infection of
293Tcells in triplicates. Luciferase activities in cell lysatesweredetermined after72 hand valuesmeasured for SARS-Spseudotypes prepared in the absence of overexpressed furinwere set
as 100%. The average of four independent experiments is shown, error bars indicate standard error of the mean (SEM). Right panel: 293T effector cells cotransfected with expression
plasmids for the indicated S-variants (or transfectedwith empty vector as control), GAL-VP16 and furin (or transfectedwith empty vector as control), were co-cultivatedwith 293T target
cells transfectedwith plasmids encoding a GAL-VP16-responsive luciferase gene and hACE2 (or transfectedwith empty vector as control) in triplicates. Luciferase activities in cell lysates
were measured two days after co-cultivation. The experiment shown is representative of three independent experiments, error bars indicate SD.
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does not depend on cathepsin activity.
SARS-S-dependent cell–cell fusion is inhibited by leupeptin
Since SARS-S-driven cell–cell fusionwasnot dependent on cathepsin-
activity, we asked if the activity of other proteasesmight be required. For
this, we ﬁrst sought to clarify to which extend SARS-S-driven cell–cell
fusion depends on the presence of exogenous trypsin, since previous
studies reported that efﬁcient SARS-S-driven cell–cell fusion occurred
only upon treatment of SARS-S expressing cells with trypsin (Howard
et al., 2008; Simmons et al., 2004), while in our experiments trypsin was
dispensable for robust cell–cell fusion (Figs. 5, 6 and 8). When we
examined fusion of SARS-S or VSV-G transfected 293T cells with control
transfected 293T cells (which express low levels of endogenous ACE2
(Hofmann et al., 2004a; Li et al., 2003; Simmons et al., 2004)), we found
that trypsin treatment was required for SARS-S- but not VSV-G-driven
cell–cell fusion, and that fusion driven by VSV-G but not SARS-S was
induced by low pH (Fig. 9A). However, when cell–cell fusion with ACE2
transfected 293T cells was examined, robust SARS-S-driven fusion was
already observed in the absence of trypsin treatment, and the fusionFig. 7. Proteolytic processing of wt SARS-S and SARS-S mutant T760R in the presence
and absence of furin overexpression.The indicated S-proteins were transiently
expressed in 293T cells in the absence and presence of furin (expression plasmids for
SARS-S and furin were transfected at a 1:1 ratio), the cells treated with PBS or trypsin as
indicated and cell lysates analyzed with S2-speciﬁc antiserum. As control, ß-actin
expression in cell lysates was assessed. The results of a single gel are shown fromwhich
irrelevant lanes were removed.activitywas further augmented in the presence of trypsin (Fig. 9A). Thus,
SARS-S-driven cell–cell fusion depends on trypsin-activation of SARS-S
only if receptor levels are limiting. If ACE2 is expressed at high levels,
robust fusion occurs in the absence of trypsin and is most likely due to
SARS-S activation by a host cell protease other than cathepsins.
In order to investigate the need for a host cell protease for trypsin-
independent SARS-S-driven cell–cell fusion, we inhibited the wt
SARS-S-driven cell–cell fusion reaction by leupeptin, an inhibitor of
cysteine and serine protease, AEBSF, a serine protease inhibitor, and
the cathepsin inhibitors E64c andMDL28170. All inhibitors were used
at non-cytotoxic concentrations, as determined by a commercially
available cytotoxicity assay (Promega, Madison, USA) and by the lack
of inhibition of luciferase expression in cells cotransfected with the
reporter plasmids employed to quantify cell–cell fusion (Supplemen-
tary Fig. 2). Of all inhibitors tested, only leupeptin inhibited SARS-S-
driven cell–cell fusion, and inhibition was dose-dependent (Fig. 9B).
Finally, leupeptin, E64c and MDL28170 inhibited SARS-S-driven
virus–cell fusion (Fig. 9C), as expected from the results shown in
Fig. 8 and from previous work (Simmons et al., 2005). Thus, SARS-S-
driven cell–cell fusion depends on the activity of a so far unchar-
acterized cysteine or serine protease, while virus–cell fusion requires
cathepsin activity.Discussion
The processing of SARS-S by cellular proteases might determine
route and efﬁciency of viral entry into target cells and might have
important consequences for developmentof preventive and therapeutic
strategies (Belouzard et al., 2009; Simmons et al., 2005;Watanabe et al.,
2008). However, the sites in SARS-S, which are recognized by host cell
proteases, are incompletely deﬁned. We show that R667 deﬁnes a
trypsin sensitive site, which is required for inactivation of cell-free virus
by trypsin and for trypsin-dependent infectious entry of cell-bound
virus into targets pretreated with ammonium chloride. In contrast, the
integrity of R667was dispensable for infectious entry in cell culture and
activation of SARS-S-driven virus–virus fusion by trypsin and cathepsin
L. Optimization of an existing minimal furin cleavage site, 758-RNTR-
761, by mutation T760R augmented SARS-S-driven cell–cell and virus–
cell fusion. However, no evidence for cleavage of SARS-S at this motif
was obtained. Finally, differential blockade of SARS-S-driven virus–cell
and cell–cell fusion by protease inhibitors showed that these processes
depend on different activating proteases, with a so far poorly
Fig. 8. Impact of the cathepsin B/L inhibitor MDL 28170 on virus–cell (left panel) and cell–cell fusion (right panel) driven by wt SARS-S and SARS-S mutant T760R. Left panel: 293T
target cells were pre-incubated with the indicated concentrations of MDL 28170 for 1 h and thereafter infected in quadruplicateswith infectivity-normalized pseudotypes bearing
the indicated S-proteins. Luciferase activities in cell lysates were determined at 72 h post infection. The results of a representative experiment carried out in triplicates are shown and
were conﬁrmed in two separate experiments. Right panel: 293T target cells transfected with gal5-luc and either pcDNA3 (control) or ACE2 were mixed with effector cells expressing
GAL-VP16 in combination with the indicated S-proteins. After mixing, cells were either left untreated or treated with 1 μM MDL 28170. Luciferase activities were determined two
days after mixing. The results of a representative experiment are shown; comparable results were obtained in an independent experiment. Error bars indicate SD.
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driven cell–cell fusion.
The spike protein of SARS-CoV contains several potentially protease
sensitive sites, which have been implicated in proteolytic processing of
SARS-S (Belouzard et al., 2009; Bergeron et al., 2005; Follis et al., 2006).
The most N-terminal motif, amino acids 657 to 676, shows some
similarity to cleavage sites of other coronavirus S-proteins but does not
comprise an RXXR motif recognized by proprotein convertases in the
context of cleavable coronavirus S-proteins (Follis et al., 2006).
Nevertheless, mutation of R667 was reported to block the increase in
SARS-S membrane fusion activity observed for wt SARS-S upon furin
overexpression, and introduction of a furin consensus sequence at this
site was shown to increase SARS-S-driven cell–cell fusion (Belouzard et
al., 2009; Follis et al., 2006). Our results demonstrate that this site is
important for SARS-S cleavage by trypsin, and that trypsin cleavage
depends on the presence of R667 but not K672. Thus, cell-free virions
bearing wt SARS-S but not SARS-S mutant R667A were inactivated by
trypsin, while cell-bound virions bearing wt SARS-S but not mutant
R667A were activated by trypsin for infection of ammonium chloride
pretreated target cells (trypsin bypass). These ﬁndings are in agreement
with published work (Belouzard et al., 2009; Follis et al., 2006), and
highlight that R667 deﬁnes a protease sensitive site in SARS-S.
Unexpectedly, however, mutation of R667 was compatible with robust
SARS-S activation by trypsin and cathepsin L in a virion–virion fusion
assay. The reasons for thedifferential requirement forR667 in the trypsin
bypass and virion-virion fusion assays are at present unclear, but might
relate to different properties of the target cell membrane relative to the
virion membrane, in terms of receptor concentration and presence of
cellular proteases. Regardless of the underlying mechanism, the present
data suggest that R667 might be dispensable for activation of SARS-CoV
by trypsin and by cathepsin L. Such a scenario would be in agreement
with results by Bosch and colleagues, who mapped the cathepsin L
cleavage site in SARS-S to amino acid T678 (Bosch et al., 2008).
Belouzardet al. suggested thatproteolytic activationof SARS-Smight
be a two-step process and might involve cleavage at R667 and at R797
(Belouzard et al., 2009). Evidence for an important role of R797 in
proteolytic activation of SARS-S was obtained in cell–cell fusion and
trypsin bypass experiments, in which the SARS-S mutant R797N was
found tobe refractory to activation by trypsin (Belouzard et al., 2009). In
addition, the insertion of a furin consensus motif at this site increased
SARS-S activity in a cell–cell fusion assay (Belouzard et al., 2009) and, as
documented by an independent study, allowed cathepsin-independentinfectious entry into target cells (Watanabe et al., 2008). Notably, a
minimal furin cleavage site, RXXR, is present in SARS-S at amino acids
758 to 761, and a peptide spanning this motif was previously shown to
be cleaved by furin, while peptides spanning R667 and R797 were not
recognized by the protease (Bergeron et al., 2005). We found that
optimizing the minimal furin site at position 758 (mutant T760R)
signiﬁcantly increased SARS-S activity in cell–cell and virus–cell fusion
assays, andwe noted that the virus–cell fusion activity of wt SARS-S but
not mutant T760R was augmented by overexpression of furin in virus-
producer cells, although this effectwasnot statistically signiﬁcant. These
results suggest that amino acids 758 to 761 might constitute an
alternative processing site, which might be recognized by proprotein
convertases or related enzymes. However, proteolytic processing of wt
SARS-S or variant T760R upon furin overexpression could not be
demonstrated, indicating that cleavage was inefﬁcient or absent.
Therefore, alternative scenarios for the role of amino acids 758 to 761
in SARS-S activation must be considered. Thus, it is possible that
augmentation of SARS-S activity upon furin overexpression and
mutation T760R were separate effects, with T760R potentially modu-
lating protease sensitivity of other sites in SARS-S.
Cell to cell fusion assays are commonly used to functionally analyze
SARS-S, including the characterization of potential proteolytic proces-
sing sites in SARS-S (Belouzard et al., 2009; Follis et al., 2006; Hofmann
et al., 2006; Simmons et al., 2003). In most studies, SARS-S-driven cell–
cell fusion was examined upon activation of SARS-S by exogenous
trypsin. However, it has so far not been determined if SARS-S-driven
cell–cell fusion can also be activated by a host cell protease. For instance,
it is unknown if the proteases responsible for proteolytic activation of
virus-associated SARS-S, cathepsins B and L, can also activate cell-
associated SARS-S.We found that trypsin-activation of SARS-Swas only
required for fusion with cells expressing low amounts of ACE2, while
fusion with target cells expressing high levels of ACE2 proceeded
efﬁciently in the absence of trypsin, in agreement with a recent study
(Glowacka et al., 2011). Under the latter conditions, cell–cell fusion
driven by SARS-S was inhibited by leupeptin but not cathepsin
inhibitors, indicating that a serine protease, or a cysteine protease
other than cathepsins B and L, can activate SARS-S for cell–cell fusion.
The identity of the responsible protease(s) is at present unclear. A role
for factor Xa, a serine protease, has been suggested but the results await
conformation (Du et al., 2007). The type II transmembrane serine
proteases (TTSPs) TMPRSS2 and TMPRSS4 can activate the inﬂuenza
virus hemagglutinin by cleavage (Böttcher et al., 2006; Chaipan et al.,
Fig. 9. SARS-S-dependent cell–cell fusion depends on the activity of a cysteine or serine
protease. (A) Target 293T cells cotransfected with a plasmid encoding β-galactosidase ω
fragment and either pcDNA3 (control) or plasmid encoding ACE2 were mixed with 293T
effector cells transiently expressing β-galactosidase α peptide in combination with either
the SARS-S or VSV-G proteins. After 1 h, cells were pulsed with different pH's or TPCK-
trypsin. After a further 5 h, β-galactosidase trans-complementation was assessed and
expressed as relative light units. The results of a representative experiment carried out in
triplicates are shown.Errorbars indicateSD. Similar resultswereobtained inan independent
experiment. (B) Target 293T cells transfectedwith gal5-luc andACE2weremixedwith293T
effector cells expressing GAL-VP16 in combination with the SARS-S-protein. Effector cells
transfectedwith empty vector (no spike) served as negative controls. Target cellswere pre-
incubatedwithPBSor the indicatedconcentrationsofprotease inhibitorsbeforemixingwith
effector cells. After mixing of cells, which involved detachment and washing of cells, the
inhibitors were replenished and cocultures were maintained for 48 h.Thereafter, luciferase
activities in cell lysateswere determined. The results of a representative experiment carried
out in triplicates are shown, cell–cell fusionmeasured in the absence of inhibitor was set as
100%. Error bars indicate SD. Similar resultswere obtained in two independentexperiments.
(C) 293T-hACE2 cellswere incubatedwith the indicated inhibitors for 1 h and subsequently
infected with infectivity-normalized pseudotypes bearing VSV-G or SARS-S. Luciferase
activities in cell lysates were determined at 72 h post infection. The results of a
representative experiment performed in triplicates are shown; error bars indicate SD.
Similar results were obtained in two independent experiments.
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for membrane fusion (Glowacka et al., 2011; Matsuyama et al., 2010;
Shulla et al., 2011). However, appreciable expression of TMPRSS2 or
TMPRSS4was not detected in 293T cells in a previous study (Bertram et
al., 2010), and SARS-S-driven cell–cell fusion was not inhibited by the
serine protease inhibitor AEBSF (present study), whichwas shown to be
active against other TTSPs (Beliveau et al., 2009). Therefore, TTSPs and
related serine proteases are unlikely to account for SARS-S activation
under the conditions tested here, and future studies should focus on the
role of cysteine proteases.
Materials and methods
Plasmid construction and in vitro-mutagenesis
Expression plasmids pCAGGS-SARS-S, encoding the spike proteins
of SARS-CoV strain Frankfurt (Hofmann et al., 2004b) or Urbani
(Simmons et al., 2003), and pcDNA3-hACE2, encoding the human
ACE2 receptor, have been described previously (Hofmann et al.,
2004b, 2004a). Site-directed mutagenesis of the SARS-S-protein was
performed by overlap-extension PCR. For generation of mutation
T760L the following overlapping primers were used: p5 SARS-S T760R
(5-CCGACGTGAAGTGTTCGCTCAAGTC-3) and p3 SARS-S T760R (5-
GACTTGAGCGAA.
CACTTCACGTCGGTTGCGATCCTGTTCAGCAGCAATACC-3). To facili-
tate generation of PCR fragments bearing the desired mutations, only
the 3′ prime portion of the S-sequencewas ampliﬁed using overlapping
PCR. Subsequently, the PCR-ampliﬁed fragmentswere introduced into a
pCAGGS variant harbouring the corresponding 5′ portion of the SARS-S
sequence. Variants R667A, K672L and KPTKR to EPTED were generated
using Quikchange site directed mutagenesis (Stratagene), with SARS-S
in pcDNA as template, and then transferred to pCAGGS. All PCR
ampliﬁed sequences were conﬁrmed by automated sequence analysis.
Cell culture
293T cells were propagated in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin
and streptomycin, and grown in a humiﬁed atmosphere of 5% CO2. 293T
cells stably expressing ACE2 (293 T-hACE2) were generated by
transfection of plasmid pcDNA3.1zeo-hACE2 (Hofmann et al., 2004a)
into 293T cells followed by selection of resistant cells with zeocin
(Invitrogen) at 50 μg/ml. Surface expression of ACE2 on clonal cells was
conﬁrmed by FACS analysis.
Cell–cell fusion assays
For analysis of cell–cell fusion, 293T effector cells seeded in 6-well
plates at 3×105/well were CaPO4-cotransfected with plasmid pGAL4-
VP16, encoding theHerpes SimplexVP16 transactivator fused to theDNA
bindingdomain of the yeast transcription factorGAL4 (Stamminger et al.,
2002), and plasmids encoding SARS-S-variants (or empty plasmid) and
furin (or empty plasmid). In parallel, 293T target cellswere seeded in 48-
well plates at 3×104/well and transfected with pcDNA3 or the hACE2
expression plasmid together with plasmid pGal5-luc, in which luciferase
reporter gene expression is controlled by ﬁve GAL4 binding sites
(Stamminger et al., 2002). The day after transfection, effector cells
were diluted in fresh medium and added to the target cells. Cell–cell
fusion was quantiﬁed by determination of luciferase activities in cell
lysates 48 h after cocultivation using a commercially available kit
(Promega, Madison, USA). Results generated in the experimental system
described earlier are shown in Figs. 5, 6, 8 and 9B. Alternatively, cell–cell
fusion was assayed using α-complementation of β-galactosidase frag-
ments, as previously described for HIV (Holland et al., 2004). For this,
effector293Tcellswere co-transfectedwithplasmidsencodingSARS-Sor
VSV-G and a plasmid encoding an N-terminal fragment of β-
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cells were co-transfected with a plasmid encoding ACE2 or with the
corresponding empty plasmid and a plasmid encoding the remaining C-
terminal portion of β-galactosidase (amino-acids 80–1023; termed ω
fragment). The day after transfection, effector cells were diluted in fresh
medium and added to the target cells at a ratio of 1:1. After one hour
incubation for attachment and binding, cells were washed in serum-free
medium and pulsed with medium adjusted to pH5.0, pH7.0, pH8.0 or
containing TPCK-trypsin at 15 μg/ml for 10 min at 37 °C. pH or trypsin
was neutralized by the addition of excessmedium containing serum and
trypsin inhibitor. Cells were then incubated for a further 5 h. Upon viral
envelope-drivenmembrane fusion theα peptides andω fragments of β-
galactosidase trans-complement each other to give functional β-
galactosidase enzymatic activity, which was detected in cell lysates
employing a commercially available kit (Galacton Plus substrate, Applied
Biosystems). Results generated in this experimental systemare shown in
Fig. 9A.
Production of lentiviral pseudotypes and infection experiments
For generation of lentiviral pseudoparticles, CaPO4 transfections
were performed as described (Hofmann et al., 2004b; Simmons et al.,
2003). Inbrief, 293 T cellswere transiently cotransfectedwithpNL4-3E-
R- Luc (Connor et al., 1995) andexpressionplasmids for SARS-S-variants
or VSV-G. For some experiments, human furinwas co-expressed during
productionof pseudoparticles. The culturemediumwas replacedat16 h
and harvested at 48 h post transfection. The supernatants were passed
through 0.45 μm ﬁlters, aliquotted and stored at −80 °C. Capsid
contents (p24) in harvested supernatants were determined using a
commercially available kit (Murex,Wiesbaden,Germany). For infection,
293Tcells or 293T cells transiently transfectedwithpcDNA3orhACE2or
293T cells stably expressing hACE2 were incubated with pseudotypes,
normalized for infectivity or p24-capsid protein content, for three days
before cells were lysed and luciferase activities determined using a
commercially available kit (Promega, Madison, USA).
Blockade of pseudotype infection by cathepsin inhibitors
293T cells in 96-wellswere pre-incubatedwith the cathepsin L and B
inhibitor MDL 28170 (Calbiochem, Darmstadt, Germany) for 30 min.
Thereafter, pseudotypes of comparable infectivity were added for 12–
16 h, the culture medium was replaced and luciferase activities in cell
extracts were determined after 72 h as described earlier.
Protease inactivation of pseudotyped viruses
Infectivity normalized pseudovirions bearing wild-type or mutant
SARS-S protein were incubated with varying amounts of protease for
30 min at room temperature. Proteolysis was halted by the addition of
an equal volume of medium containing 10% FBS, 100 μg/ml soy bean
trypsin inhibitor (STI) and100 μg/ml aprotinin.Viruswas thenplatedon
293T-ACE2 cells, spin infected for 90 min at 2500 rpm and incubated at
37 °C. After 4 h, themediumwas replacedwith freshmedium, and cells
were incubated for 48 h before measurement of luciferase activity. All
proteases were obtained from Sigma, and ﬁnal concentrations used in
the assaywere determined by preliminary experiments, or themaximal
practical level achievable based on the stock solutions of 1 mg/ml.
Proteaseswere diluted in PBS. Trypsin and chymotrypsinwere used at a
ﬁnal concentration of 25 μg/ml, elastase and factor Xa at 50 μg/ml,
thermolysin and thrombin at 125 μg/ml and plasmin at 250 μg/ml.
Trypsin bypass
Trypsin bypass experimentswereperformed asdescribed (Simmons
et al., 2005). Brieﬂy, 293T-ACE2 cells were pretreated for 1 h with cold
medium containing ammonium chloride (40 mM). An equal volume ofdiluted cold pseudovirion mixture (virus was ultracentrifuge-concen-
trated and resuspended in PBS to remove FBS) was added, and the cells
were spin-infected at 4 °C to allow virus-binding to cells. The medium
was replaced with warm serum-free medium containing ammonium
chloride (20 mM) and incubated at 37 °C for 15 min. Subsequently, the
medium was removed, and fresh medium containing TPCK-trypsin
(10 μg/ml) was added for 10 min at 25 °C. The trypsin-containing
mediumwas then removedandmediumsupplementedwithSTI (75 μg/
ml) and ammonium chloride (20 mM) was added. After a 12 h
incubation period, medium was replaced with fresh medium without
ammonium chloride, and cells were incubated for a further 36 h before
luciferase activity was measured.
Virus–virus fusion assay
Virus to virus fusion was assayed as described (Simmons et al.,
2005). Brieﬂy, equal amounts of pseudovirions bearing either ACE2 and
encoding luciferase as a reporter (HIV-luc(ACE2)) or both SARS-CoV
Spike (or mutants) and Avian Sarcoma Leukosis Virus-A envelope and
encodingGFP (HIV-gfp(S+E))weremixed and incubated for 30 minon
ice to allow binding. The temperature was then raised to 37 °C for
15 min to allow induction of conformational rearrangements. Particles
were then either treatedwith 10 ug/ml TPCK-trypsin (Sigma) or the pH
was lowered topH6by the additionof 0.1 Mcitric acid, andpreactivated
recombinant cathepsin L was added to a ﬁnal concentration of 2 ug/ml.
Proteolysis was halted after 10 min at 25 °C by addition of soybean
trypsin inhibitor and leupeptin. Virus mixtures were then diluted and
used to infect HeLa cells stably expressing Tva that had been pretreated
with 20 μg/ml leupeptin for 1 h.
Analysis of SARS-S expression by Western blot
Cells transiently expressing SARS-S or VLPs harbouring SARS-Swere
lysed in SDS-Laemmli buffer and boiled for 15–30 min at 95 °C. Samples
were separated via 12.5% SDS-PAGE and transferred onto nitrocellulose
membranes (Schleicher & Schuell, Dassel, Germany). SARS-S proteins
were detected by staining with SARS-S speciﬁc rabbit serum (Imgenex,
San Diego, USA) at a 1:1000 dilution, followed by detection of bound
antibodies by use of a peroxidase-conjugated anti-rabbit IgG (Dianova,
Hamburg, Germany) at a dilution of 1:5000. For loading control, the
stripped membranes were incubated with an anti-ß-actin antibody
(Sigma, Deisenhofen, Germany) at a 1:1000 dilution, followed by
incubation with peroxidase-conjugated anti-mouse IgG (Dianova,
Hamburg, Germany) at a dilution of 1:5000. Chemiluminescence
detection was performed employing a commercially available kit,
according to the manufacturer's protocol (ECL Western detection kit;
Amersham Pharmacia Biotech Europe, Freiburg, Germany).
Statistics
Statistical signiﬁcance was calculated employing a two-tailed
student's t-test for dependent samples.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.02.020.
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